Companies that offer to test a customer's genome for propensities toward disease states are still offering their services despite a threat from a leading congressional Democrat to shut them down, and all indications are that regulatory bodies see the issue as less than critical despite comments heard from the congressional panel in a July hearing. (Medical Device Daily) Read More
